Ensign Peak Advisors
MNTA

Ensign Peak Advisors’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Ensign Peak Advisors’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-103,873
Closed -$3.46M – 1775
2020
Q2 		$3.46M Hold
103,873
– – 0.01% 722
2020
Q1 		$2.83M Buy
103,873
+21,600
+26% +$601K 0.01% 687
2019
Q4 		$1.62M Buy
+82,273
New +$1.32M ﹤0.01% 1148

Other funds holding MNTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return

Ensign Peak Advisors's MNTA Position: Q3 2020 in Review

Ensign Peak Advisors sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q3 2020, closing a stake of 103,873 shares — an estimated $3.46M sold.

Ensign Peak Advisors first reported a position in MNTA in Q4 2019 and held it in 3 quarters. The position peaked at $3.46M in Q2 2020. 211 funds tracked by Wall St. Rank hold MNTA as of Q3 2020.

  • Ensign Peak Advisors reported no remaining Momenta Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • Ensign Peak Advisors sold 103,873 Momenta Pharmaceuticals, Inc. shares in Q3 2020, an estimated $3.46M.
  • Ensign Peak Advisors first reported a position in Momenta Pharmaceuticals, Inc. in Q4 2019 and held it in 3 quarters.
  • Ensign Peak Advisors's Momenta Pharmaceuticals, Inc. position peaked at $3.46M in Q2 2020.
  • 211 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q3 2020.

Based on Ensign Peak Advisors's 13F filing for Q3 2020, filed 12 Nov 2020.